Bulk Inquiry
Quininib
- Soluble in DMSO
- MF: C17H13NO
- MW: 247.29
Description
Quininib is a potent cysteinyl leukotriene (CysLT) antagonist with IC50 values of 1.4 μM and 38.5 μM at CysLT1 and cysLT2 receptors, respectively. Quininib inhibits downstream p-ERK signaling to reduce pro-inflammatory cytokines like IL-6 and IL-8. Mechanistically, it suppresses pathological neovascularization and tumor growth via a distinct pathway completely independent of classical VEGF signaling.
CysLT pharmacology is highly relevant to cancer biology. Quininib serves as a vital tool to support mechanistic studies of CysLT receptors, VEGF-independent pathways, and LTD4 signaling across biochemical, cellular, and disease-model assays.
Key Features
- CysLT antagonist
- IC50 values 1.4 μM (CysLT1) and 38.5 μM (CysLT2)
- Supports focused CysLT pathway studies in biochemical and cellular systems
- Suppresses pathological neovascularization independently of VEGF pathways
Applications
- CysLT pharmacology and target-validation studies
- CysLT pathway and signaling assays
- Disease-model research related to cancer
- Receptor signaling, ligand profiling and functional response assays
More Information
| Parent CAS No. | 143816-42-6 |
|---|---|
| Chemical Name | (E)-2-(2-(quinolin-2-yl)vinyl)phenol |
| SMILES | C1(O)=CC=CC=C1/C=C/C1C=CC2C(N=1)=CC=CC=2 |
| MFCD | N.A. |
| InChi | InChI=1S/C17H13NO/c19-17-8-4-2-6-14(17)10-12-15-11-9-13-5-1-3-7-16(13)18-15/h1-12,19H/b12-10+ |
| InChiKey | NXNDEWNGCMCWMA-ZRDIBKRKSA-N |
| CID | 135411330 |
| Short Description | CysLT antagonist |
References
- AL Reynolds et al. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. J Biol Chem. 2016 Apr 1;291(14):7242-55.
- O Galvin et al. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo. J Control Release. 2016 Jul 10;233:198-207.
- AG Murphy et al. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. Sci Rep. 2016 Oct 14;6:34523.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1310 | Myoseverin |
From $137.50 |
| 1418 | JWH 133 |
From $132.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1548 | LBH 589 |
From $99.00 |
| 1699 | Temsirolimus |
From $104.50 |
| 1768 | AMG 706 |
From $115.50 |
| 1793 | Lenalidomide |
From $44.00 |
| 2234 | SSR 128129E |
From $121.00 |
| 2332 | OTX 008 |
From $137.50 |
| 2553 | LY 2801653 |
From $132.00 |
| 2738 | CysLT1 Antagonist Q8 |
From $104.50 |
